OKYO Pharma Limited: Result of Annual General Meeting
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed. The voting results showed overwhelming support, with key resolutions such as the approval of the report and accounts receiving 99.99852% approval. Shareholders, totaling 1,415,040,468 ordinary shares, participated actively in the voting process. The resolutions included the re-election of directors and the appointment of auditors, reflecting strong governance practices and shareholder confidence in the company's direction.
Positive
- All resolutions at the AGM were passed with strong shareholder support, particularly the report and accounts with 99.99852% approval.
- High level of shareholder participation with 1,415,040,468 shares voted, indicating robust shareholder engagement.
Negative
- None.
Details
News Market Reaction – OKYO
The recorded move for OKYO in the trading session of this news was +5.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting ("AGM") of the Company held earlier today all resolutions were duly passed.
The result of the poll, including the proxy voting, is as follows:
| For | Against | Discretion | Withheld | For + Discretion | ||||||||
| Resolution | Description | Votes | % Votes Cast | Votes | % Votes Cast | Votes | % Votes Cast | Votes | Total Votes Cast (excl. Votes Withheld) | Votes | % Votes Cast | |
| RES:001 | REPORT AND ACCOUNTS | 560,824,152 | 325 | 8,000 | 3,000 | 560,832,477 | 560,832,152 | 99.99994 | % | |||
| RES:002 | REMUNERATION REPORT | 560,789,302 | 33,975 | 8,000 | 4,200 | 560,831,277 | 560,797,302 | 99.99394 | % | |||
| RES:003 | RE-ELECT MR W SIMON | 560,823,652 | 825 | 8,000 | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||
| RES:004 | RE-ELECT DR.G S. JACOB | 560,823,652 | 825 | 8,000 | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||
| RES:005 | RE-ELECT MR J BRANCACCIO | 560,823,652 | 825 | 8,000 | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||
| RES:006 | RE-ELECT MR G CERRONE | 560,812,452 | 12,025 | 8,000 | 3,000 | 560,832,477 | 560,820,452 | 99.99786 | % | |||
| RES:007 | RE-ELECT MR.B DENOYER | 560,812,952 | 10,325 | 8,000 | 4,200 | 560,831,277 | 560,820,952 | 99.99816 | % | |||
| RES:008 | APPOINTMENT OF AUDITORS | 560,823,652 | 825 | 8,000 | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||
| RES:009 | DIRECTORS TO ALLOT SHARES | 560,822,952 | 325 | 8,000 | 4,200 | 560,831,277 | 560,830,952 | 99.99994 | % | |||
| RES:010 | PRE-EMPTION RIGHTS | 560,789,802 | 33,475 | 8,000 | 4,200 | 560,831,277 | 560,797,802 | 99.99403 | % | |||
Further information on votes:
As at 17 August 2022, there were 1,415,040,468 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.
The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the AGM itself, and will be available on the National Storage Mechanism, https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The result of poll and proxy voting will also be available on the Company's website, www.okyopharma.com.
| Enquiries: | ||
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | Tel: +44 (0)20 7495 2379 |
| Gabriele Cerrone, Non-Executive Chairman | ||
| Optiva Securities Limited (Broker) | Robert Emmet | Tel: +44 (0)20 3981 4173 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.